Following treatment, these aged-treated mice quickly developed tumours within days, which highlights the strong tumour-promoting effect of BRAFi in Hras mutant skin and models the development of cSCC in melanoma patients with Hras mutations (Fig. 1f). Here, HRAS is linked to skin squamous cell carcinoma.